Kyoko Watanabe
Managing Director at DEFTA Partners
San Francisco, California
Overview
Work Experience
Board Observer
2022 - Current
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.
Raised $65,018,792.00 from DEFTA Partners, Kairos Ventures, Bios Partners, Kairos Ventures, DEFTA Partners, Tech Coast Angels and Bios Partners.
Board Observer
2022
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
Raised $256,000,000.00 from Digital Mobile Venture.
Managing Director
1997
Managing Director
1996
Founded in 1984, DEFTA Partners has been actively identifying nurturing and funding companies that are focused on developing high technologies in the US, Japan, Israel and Europe. DEFTA primarily make seed and first round investments in early stage information technology and healthcare technology companies. www.deftaparnters.com
Board Member
2019
InformAI has a healthcare focus on AI solutions that speed up medical diagnosis at the point-of-care and improve radiologist productivity. Our AI-enabled image classifiers and patient outcome predictors are developed within the world’s largest medical center complex, the Texas Medical Center. Together with our partners, InformAI is transforming the way healthcare is being delivered.
Board Member
2019
'iMedrix developed KardioScreen, a CE certified mobile/portable hospital grade digital ECG. KardioScreen is being used at a number of leading hospitals in a variety of use cases. Kardioscreen is accurate and comprehensive in its analysis, even in the toughest of field conditions.
Board Member
2015
http://welcome.1worldonline.com/
Owner
2008
http://www.condorvalley.org/
Board Member
2002
Cisco DevNet is your source for everything developer at Cisco Systems.
Board of Director
1994
Board Member
2019 - 2023
DiA Imaging Analysis provides advanced AI-based ultrasound analysis technology that makes ultrasound accessible to all. DiA’s automated tools deliver fast and accurate clinical indications to support the decision making process and offer better patient care. DiA’s AI-based technology uses advanced pattern recognition and machine-learning algorithms to automatically imitate the way the human eye detects image borders and identifies motion. Using DiA’s tools provides automated and objective AI tools, helps reduce variability among users, and increases efficiency. It allows clinicians with various levels of experience to quickly and easily analyze ultrasound images. (Acquired by Philips) www.dia-analysis.com.